When our co-founders launched the site in 2010, they wondered whether there would be enough retractions to write about on a regular basis. Five+ years and three full-time staffers later, and we simply don’t have the time to cover everything that comes across our desk.
In 2012, we covered a group of duplication retractions in a single post, simply because duplications happen so frequently (sadly) and often don’t tell an interesting story. So in the interest of bookkeeping, we’re picking up the practice again.
Here are five unrelated retractions for your perusal: all addressing duplications, in which the same – or mostly the same – authors published the same – or mostly the same – information in two different – or sometimes the same – journals.
So, on the buffet table we offer the following entrees: Continue reading You’ve been dupe’d: Meet authors who like their work so much, they publish it twice
Researchers at the University of Pittsburgh have retracted a paper on using thalidomide, which led to an estimated 10,000 birth defects by the time the drug was pulled from the market in 1961, to prevent chemo-induced sterility.
Alkylating agents, which prevent DNA replication in cells, are a commonly-used cancer treatment. Unfortunately they also damage the ovaries and testes, sometimes causing infertility. The University of Pittsburgh scientists published a paper in Elsevier journal Fertility and Sterility in 2011 that suggested thalidomide, which causes severe birth defects when used during pregnancy, might help protect ovaries during chemo.
However, according to the notice, the authors tried and failed to replicate their results. They had two separate scientists who were not authors take a look at the results; everyone agreed that the original study incorrectly reported the number of primordial follicles, the precursor to mature eggs.
Here’s the notice for “Thalidomide treatment attenuates chemotherapy-induced gonadal toxicity”: Continue reading Thalidomide paper retracted for lab error